DSGN: Rega marang dodolan Design Pharma
High profit margins are supported by the precise delivery of biomaterials and temperature control. The current price-to-sales ratio clearly demonstrates market expectations, where serves as the base parameter value. Investors trust the small molecule developments for combating hereditary pathologies, while a staff of leading biologists is retained through a system of premium options for Design Therapeutics (DSGN).
Rincian analitis perusahaan Design Pharma (DSGN)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Utang Agregat marang Ekuitas Design Therapeutics|DSGN - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Design Corp|DSGN - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Design Pharma|DSGN - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Design Therapeutics|Koefisien jangkoan perantara designtx.com
- informasi bathi lan kelipatan valuasi:
DSGN - Bathi resik|Bathi mangsa ngarep Design Therapeutics|DSGN - Rasio rega marang bathi|Kapitalisasi marang proyeksi bathi Design Therapeutics Inc|DSGN - Pangali PEG|Nilai perusahaan marang bathi operasional sadurunge panyusutan Design Pharma|DSGN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Design Therapeutics|DSGN - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham sajroning taun lumaku designtx.com|DSGN - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Design Therapeutics
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:DSGN designtx.com
The P/S ratio of reflects the market value of Design Therapeutics relative to its revenue, measuring the extent of business overvaluation or undervaluation through the ratio of market capitalization to sales. By analyzing historical P/S levels, an investor can identify asset overheating, which is critical for DSGN as the current valuation is based on future gene therapy validation and the success of clinical trials.
Karo sapa Design Therapeutics saingan
TEM (Tempus AI) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S QGEN (Qiagen)|Ionis Pharmaceuticals, Inc. (IONS) - Rega marang dodolan|RGEN - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RNA (Avidity Corp)|CRSP: Multiplikator P/S|genedx.com (WGS) - Multiplikator P/S|Rasio rega marang pendapatan Ultragenyx|Beam Therapeutics Inc - Rasio rega marang dodolan|Multiplikator P/S SRPT|TWST - Rega marang dodolan|10x Genomics, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S intelliatx.com NTLA|STOK: Kapitalisasi marang pendapatan|BioLife Solutions Inc - Kapitalisasi marang volume dodolan|WVE: Multiplikator P/S|MAZE - Koefisien rega marang pendapatan|SION (Sionna Therapeutics Inc) - Multiplikator P/S|Kapitalisasi marang pendapatan primemedicine.com (PRME)|Rasio rega marang pendapatan Taysha Gene Therapies, Inc. (TSHA)|Koefisien rega marang pendapatan uniQure NV|Multiplikator P/S MGTX (MeiraGTx PLC)|RGNX: Rasio kapitalisasi marang pendapatan|SLDB - Rasio rega marang pendapatan|Koefisien rega marang pendapatan ocugen.com OCGN|PACB: Multiplikator P/S|Multiplikator rega marang pendapatan Benitec Biopharma Inc BNTC|Rasio rega marang pendapatan Rocket Pharmaceuticals Inc|Rasio kapitalisasi marang pendapatan FDMT (4D Molecular Corp)|Multiplikator P/S LXEO|korrobio.com - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Editas Medicine EDIT|SLN: Rasio kapitalisasi marang pendapatan|ProQR Therapeutics NV - Multiplikator P/S|CDXS - Multiplikator P/S|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|MGX (Metagenomi) - Multiplikator P/S|Rega marang dodolan precisionbiosciences.com DTIL|Rasio rega marang pendapatan Generation Bio Co. (GBIO)|Koefisien rega marang pendapatan Boundless Bio Inc|Multiplikator P/S XCUR (Exicure)|Koefisien rega marang pendapatan Imunon Inc (IMNN)|RXi Pharmaceuticals - Multiplikator P/S|Multiplikator rega marang pendapatan Mustang Bio, Inc. (MBIO)|transcodetherapeutics.com (RNAZ) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan BNGO|Kapitalisasi marang pendapatan APDN|BLUE: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan IPA (ImmunoPrecise Antibodies)|Kapitalisasi marang volume dodolan OMGA|Multiplikator P/S OMIC (Singular Genomics Systems Inc)|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals - Multiplikator P/S|Rega marang dodolan telesisbio.com|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology Inc. - Rasio kapitalisasi pasar marang pendapatan
